Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 3/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.62 |
| ▸ | GCK | P35557 | 1/20 | 0.54 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.51 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.51 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.51 |
| ▸ | SGMS2 | Q8NHU3 | 2/20 | 0.51 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5485828 | 0.89 | SMPD1 (0.70) | SMPD1HDAC1HDAC8HDAC6FOLH1 | |
| SCHEMBL6687841 | 0.88 | SMPD1 (0.65) | SMPD1HDAC1HDAC8HDAC6GCK | |
| SCHEMBL1649243 | 0.87 | FOLH1 (0.68) | FOLH1NPC1NR4A2NR4A1NR4A3 | |
| SCHEMBL14508840 | 0.84 | FOLH1 (0.66) | SMPD1HDAC1HDAC8HDAC6FOLH1 | |
| SCHEMBL1646582 | 0.83 | RXRA (0.56) | SMPD1HDAC1HDAC8HDAC6FOLH1 | |
| SCHEMBL19667131 | 0.83 | LRRK2 (0.64) | SMPD1HDAC1HDAC8HDAC6FOLH1 | |
| SCHEMBL6687833 | 0.83 | HDAC8 (0.73) | SMPD1HDAC1HDAC8HDAC6NPC1 | |
| SCHEMBL974381 | 0.82 | SGMS2 (0.72) | NPC1SGMS2MEN1KMT2A | |
| SCHEMBL1316640 | 0.82 | ALDH1A1 (0.56) | FOLH1NR4A2NR4A1NR4A3PTGER1 | |
| SCHEMBL383169 | 0.81 | FOLH1 (0.53) | FOLH1NR4A2NR4A1NR4A3PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040186081-A1 | Naaladase inhibitors for treating opioid tolerance | GUILFORD PHARMACEUTICALS INC. | 2004-09-23 | — | — | US | claimed |
| WO-2004078180-A2 | NAALADASE INHIBITORS FOR TREATING OPIOID TOLERANCE | GUILFORD PHARMACEUTICALS INC. (US) | 2004-09-16 | — | — | WO | claimed |
| EP-1292601-A2 | NAALADASE INHIBITORS FOR TREATING RETINAL DISORDERS AND GLAUCOMA | GUILFORD PHARMACEUTICALS INC. (US) | 2003-03-19 | — | — | EP | claimed |
| US-20030036534-A1 | Naaladase inhibitors for treating retinal disorders and glaucoma | EISAI INC. | 2003-02-20 | — | — | US | claimed |
| WO-2001092274-A2 | NAALADASE INHIBITORS FOR TREATING RETINAL DISORDERS AND GLAUCOMA | GUILFORD PHARMACEUTICALS INC. (US) | 2001-12-06 | — | — | WO | claimed |
| US-7220780-B2 | Naaladase inhibitors for treating retinal disorders and glaucoma | GUILFORD PHARMACEUTICALS INC. (US) | 2007-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186081-A1 | Naaladase inhibitors for treating opioid tolerance | OPRD1, OPRK1, OPRM1 | SMPD1 713/4885HDAC1 606/4885HDAC8 1064/4885 |
| US-20030036534-A1 | Naaladase inhibitors for treating retinal disorders and glaucoma | ALDH1A2, GAA, PDE6A | SMPD1 25/4885HDAC1 1579/4885HDAC8 1366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.